Comparative Pharmacology
Head-to-head clinical analysis: BONTRIL versus SUPRENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONTRIL versus SUPRENZA.
BONTRIL vs SUPRENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
BONTRIL 50 mg orally once daily, with or without food.
Adults: 200 mg orally twice daily with meals.
None Documented
None Documented
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Category C
Category C
Sympathomimetic Anorectic
Sympathomimetic Anorectic